A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.

Also called NCT05872269

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05872269
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05872269. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-20 (actual); primary completion 2025-01-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
Condition
NAFLD
Condition
Obesity
Condition
Dyslipidemias
Intervention (Drug)
Saroglitazar
Lead sponsor
Zydus Lifesciences Limited (class: industry)

Record details

Record id
cardio:ct-nct05872269
Content hash
09729b785b90129f3bcbf9198f11bb0d21c164dee545e04be87f7d1e6d9cf97d